Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
1. SNY reported Q2 sales of €9.99B, missing expectations by €0.2B. 2. Sales grew 6% YoY, driven by immunology and new pharmaceutical launches. 3. First-half operating income rose 8.6%, despite a 2.4% YoY drop this quarter. 4. 2025 sales guidance raised to high single digits in constant currency. 5. SNY plans a €5B share buyback, with more than 80% already completed.